Pfizer (NYSE:PFE – Get Free Report) was upgraded by equities researchers at Wall Street Zen from a “hold” rating to a “buy” rating in a note issued to investors on Saturday, Wall Street Zen reports.
A number of other equities research analysts have also commented on PFE. Citigroup upped their price target on Pfizer from $27.00 to $30.00 and gave the company a “neutral” rating in a research report on Wednesday, November 4th. JPMorgan Chase & Co. lifted their price objective on Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a research note on Friday, October 9th. Freedom Broker upped their target price on Pfizer from $33.00 to $34.00 and gave the company a “buy” rating in a report on Friday, November 6th. Cantor Fitzgerald increased their target price on shares of Pfizer from $27.00 to $28.00 and gave the company a “neutral” rating in a research report on Thursday, October 8th. Finally, FBN Securities set a $34.00 price target on shares of Pfizer in a report on Friday, November 6th. Six analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $30.32.
Read Our Latest Analysis on Pfizer
Pfizer Price Performance
Pfizer (NYSE:PFE – Get Free Report) last posted its quarterly earnings data on Tuesday, November 3rd. The biopharmaceutical company reported $0.87 earnings per share for the quarter, beating analysts’ consensus estimates of $0.74 by $0.13. The business had revenue of $16.58 billion during the quarter, compared to the consensus estimate of $15.85 billion. Pfizer had a return on equity of 19.88% and a net margin of 6.34%. Pfizer’s quarterly revenue was down .4% on a year-over-year basis. During the same period in the prior year, the business posted $0.87 earnings per share. Sell-side analysts predict that Pfizer will post 3.04 earnings per share for the current year.
Institutional Investors Weigh In On Pfizer
Institutional investors and hedge funds have recently made changes to their positions in the business. Retirement Wealth Solutions LLC lifted its stake in Pfizer by 144.6% in the third quarter. Retirement Wealth Solutions LLC now owns 861 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 509 shares during the period. Keb Asset Management LLC acquired a new stake in shares of Pfizer during the 2nd quarter worth approximately $26,000. Field & Main Bank acquired a new stake in shares of Pfizer during the 2nd quarter worth approximately $27,000. Bullseye Investment Management LLC bought a new stake in shares of Pfizer in the 2nd quarter valued at $28,000. Finally, Timbuktu Capital Management LLC bought a new stake in shares of Pfizer in the 2nd quarter valued at $29,000. Institutional investors own 68.36% of the company’s stock.
Pfizer News Roundup
Here’s some of the latest news about PFE:
- Positive Sentiment: Pfizer raised its 2026 revenue forecast by $1.5 billion, a constructive outlook signal. The company had also beaten Q3 earnings and revenue expectations, though investors did not respond positively to the results. Pfizer Just Raised Its 2026 Revenue Forecast by $1.5 Billion
- Positive Sentiment: Blackstone Life Sciences will fund up to $1.5 billion of berobenatide development costs through 2028. The deal helps fund Pfizer’s obesity-drug program while Pfizer retains control, although Blackstone will receive milestone-based payments. Pfizer and Blackstone Life Sciences Announce Strategic Funding Agreement
- Neutral Sentiment: Pfizer’s high dividend yield may attract income investors, but commentary cautions that a record-high yield can also reflect concerns about the sustainability of the payout. A Record-High Dividend Yield Can Be a Warning Sign
Pfizer Company Profile
Pfizer Inc. is a global biopharmaceutical company that researches, develops, manufactures and commercializes prescription medicines and vaccines. Its work spans areas including oncology, vaccines, internal medicine, inflammation and immunology, rare diseases, and infectious diseases. The company’s products include the Prevnar family of vaccines and medicines such as Eliquis, which it commercializes with Bristol Myers Squibb, and Paxlovid. Pfizer also developed the Comirnaty COVID-19 vaccine with BioNTech.
Further Reading
- Five stocks we like better than Pfizer
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.
